• Cytodyn request FDA EUA for M/M population due to CD10
• Cytodyn request FDA EUA for M/M population due to CD10 trial data
• NEWS2 statistically significant (secondary endpoint) 2.5x better than placebo
• 70% SAE, AEs from study in placebo arm
• P3 study if no EUA from any country (~ 75-85 patients) due to NEWS2 score being already achieved and safety already established
1
CytoDyn Inc (CYDY) Stock Research Links
Scroll down for more posts ▼
Top 10 Most Recent News Articles
Making Waves in the U.S. with K-Beauty SUNGBOON EDITOR and Milk Touch just rolled into Target Beauty Studio, making a splash in the world of K-beauty. From ingredients that boast serious benefits to playful cosmetics that let you express yourself, these brands are shaking up American beauty routines in a big way. Ingredient-Focused Skincare for Every American Face...
Continue Reading
Paving the Way: HTX's Journey in Pakistan Rolling into the Pakistan cryptocurrency scene isn't just a 'walk in the park' for HTX—it's more like traversing a new frontier with an open map. This isn’t some hit-and-run operation; HTX is strategizing for a long haul in one of the liveliest digital market arenas in South Asia. Gathering steam with community AMAs and an X...
Continue Reading
In the sprawling world of antibody discovery, where every scrap of data can make or break the next big breakthrough, FairJourney Bio (FJBio) is pulling out all the stops. They've teamed up with Sapio Sciences to ditch the paperwork nightmares and usher in a new era of AI-driven efficiency. With operations stretching from Porto to Cambridge to sunny San Diego, they’re...
Continue Reading
Diving into the Succession Crisis in Finance Succession planning in the financial advisory space is like retirement planning for the rest of us—everyone knows it's crucial, yet too many put it off. Despite the looming retirement wave and desperate interest from the younger cohort, a staggering 42% of financial advisors are still without a documented succession game...
Continue Reading
Decades of an Unchecked Revolving Door The Environmental Protection Agency (EPA) and chemical manufacturers—a dance that’s been going on for what seems like forever. But not in the way you might hope. We're talking about a revolving door where execs and lobbyists waltz into regulatory chairs while regulators slide into cushy industry gigs. Wisner Baum LLP, a stickler...
Continue Reading
Revolutionizing Financial Operations: FutureVault's AI Approach In the dizzying whirlwind of financial services, the launch of FutureVault AI Agents is a game-changer for document management. This isn't some half-baked tool; it's a full-fledged overhaul of how compliance and operations should tick in the modern age. We've all seen it—a paper trail tangled across systems...
Continue Reading
Citrin Cooperman's Strategic Tax Move If there's one phrase that can spark a debate at a financial water cooler, it's 'transfer pricing.' Today, Citrin Cooperman is throwing its hat further into that ring with the appointment of Sean Trahan as head of their new Transfer Pricing and Value Chain Optimization Practice. This isn't just another reshuffling of office...
Continue Reading
Lumi: Changing the Car Buying Game Picture this: You're browsing for a new car, head filled with specifics like towing capacity, price points, and trim options. Usually, such queries would send you bouncing around the web, but Lectrium's Lumi promises to keep the questioning—and decision-making—right on the dealership's page. In a move set to shake up the game,...
Continue Reading
Glo Taps Top Wellness Expert for Women's Health Initiative In an industry brimming with wellness voices, it's rare to find one that marries scholarly acumen with authentic, personal teaching. Yet, this is precisely what Dr. Desi Bartlett brings to the table as she partners with Glo to offer new fitness programming specifically targeting women facing perimenopause and...
Continue Reading
When Maesa pulls back the curtain, they don't just crack it open—they fling it aside with flair. That's precisely what they're doing with their latest venture, Anecdotes by Artists, a fragrance brand that's taking its first bow exclusively at Sephora. It's not your average perfume launch; it's about the stories behind the scents and the artists who craft them. Unveiling...
Continue Reading
Top 5 Most Recently Viewed Articles
Key Amendments Approved for Baltic Horizon Fund Bonds Baltic Horizon Fund sought the approval of its bondholders for several amendments related to its EUR 42 million floating rate bonds set to mature in 2028. This written procedure occurred recently, allowing bondholders to engage in crucial decisions regarding the terms governing their investments. Voting Procedures and...
Continue Reading
Xnurta: A New Era in AI-Powered Advertising Xnurta, previously known as Xmars, has been at the forefront of innovation in AI-driven ad management solutions. By rebranding, Xnurta not only changes its name but also signifies a transformative journey into the future of advertising alongside AI advancements. A Shift Towards Agentic AI This rebranding mirrors the exciting...
Continue Reading
Harrow Health's Promising Innovations and Growth Strategy Harrow Health has recently caught the attention of financial analysts with an optimistic forecast from B. Riley. The financial services firm has raised its price target on Harrow Health (NASDAQ: HROW) shares to an impressive $73.00, significantly increasing it from the previous $50.00. Holding a Buy rating, B....
Continue Reading
F&G Annuities & Life Raises Common Stock Dividend Significantly F&G Annuities & Life, Inc. (NYSE: FG) has made an exciting announcement regarding their quarterly common stock dividend. The company revealed a remarkable 14% increase, moving from $0.22 to $0.25 per common share. This increase reflects the company’s strong performance and commitment to providing value to...
Continue Reading
MicroStrategy's Resilient Recovery After Market Setbacks MicroStrategy has recently made headlines with its remarkable recovery after a significant 16% drop in the market. This rebound raises an important question: Can a Bitcoin price surge to $100,000 continue to drive financial growth for companies invested in cryptocurrencies, especially MicroStrategy, a prominent...
Continue Reading